Role of immunohistochemistry in staging diffuse large B-cell lymphoma (DLBCL)

Dipti Talaulikar*, Jane Esther Dahlstrom, Bruce Shadbolt, Amy Broomfield, Anne McDonald

*Corresponding author for this work

    Research output: Contribution to journalArticlepeer-review

    14 Citations (Scopus)


    The use of immunohistochemistry (IHC) in staging bone marrow in non-Hodgkin's lymphoma (NHL) is largely limited to ambiguous cases, particularly those with lymphoid aggregates. Its role in routine clinical practice remains unestablished. This study aimed to determine whether the routine use of IHC in diffuse large B-cell lymphoma (DLBCL) would improve the detection of lymphomatous involvement in the bone marrow. It also sought to determine the impact of IHC on predicting survival compared with routine histological diagnosis using hematoxylin and eosin (H&E), Giemsa, and reticulin staining. The bone marrow trephines of 156 histologically proven DLBCL cases were assessed on routine histology, and IHC using two T-cell markers (CD45RO and CD3), two B-cell markers (CD20 and CD79a), and κ and γ light chains. IHC detected lymphomatous involvement on an additional 11% cases compared with histology alone. Although both routine histology and IHC were good predictors of survival, IHC was better at predicting survival on stepwise multivariate Cox regression analysis. IHC performed routinely on bone marrow trephines has the ability to improve detection of occult lymphoma in experienced hands. Furthermore, it is a better predictor of survival compared with routine histological examination alone.

    Original languageEnglish
    Pages (from-to)893-900
    Number of pages8
    JournalJournal of Histochemistry and Cytochemistry
    Issue number10
    Publication statusPublished - Oct 2008


    Dive into the research topics of 'Role of immunohistochemistry in staging diffuse large B-cell lymphoma (DLBCL)'. Together they form a unique fingerprint.

    Cite this